1. Romano A, Torres M, Fernandez J, Vega J, Mayorga C, Garcia J, Blanca M. Allergic reactions to ampicillin. Studies on the specificity and selectivity in subjects with immediate reactions. Clin Exp Allergy .1997;27:1425-1431.
2. Fuentes V.A.R, Jefferie T.M., Branch S.K., Degradation pathways of ampicillin in alkaline solutions, J Pharm Pharmacol.1997;49:843–851.
3. Wegienka LC, Weller JM. Renal tubular acidosis caused by degraded tetracycline. Arch Inter Med. 1964;114:232-235.
4. Abe Y, Yamamoto E, Yoshida H, Usui ♙, Tomita N, Kanno H, Masada S, Yokoo H, Tsuji G, Uchiyama N, Hakamatsuka T, Demizu Y, Izutsu K, Goda Y, Okuda H.Temperature-dependent formation of N-nitrosodimethylamine during the storage of ranitidine reagent powders and tablets. Chem Pharm Bull. 2020;68:1008-1012.
5. Wu Y, Zhua S, Wang J, Bu L, Deng J, Zhoua S. reactive nitrogen species in ranitidine degradation in UV/chloramine process: Transformation pathways and NDMA formation. Chemical Engineering Journal. 2021;404:126557.
6. Zhang H, Unal H, Gati C, Han GW, Liu W, Zatsepin NA, James D, Wang D, Nelson G, Weierstall U, Sawaya MR, Xu Q, Messerschmidt M, Williams GJ, Boutet S, Yefanov OM, White TA, Wang C, Ishchenko A, Tirupula KC, Desnoyer R, Coe J, Conrad CE, Fromme P, Stevens RC, Katritch V, Karnik SS, Cherezov V. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. Cell. 2015;161:833-844.
7. Asada H, Horita S, Hirata K, Shiroishi M, Shiimura Y, Iwanari H, Hamakubo T, Shimamura T, Nomura N, Kusano-Arai O, Uemura T, Suno C, Kobayashi T, Iwata S. Crystal structure of the hu-man angiotensin II type 2 receptor bound to an angiotensin II analog. Nat Struct Mol Biol. 2018;25:570-576.
8. Imaizumi S, Miura S, Yahiro E, Uehara Y, Komuro I, Saku K. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des. 2013;19:3002-3008.
9. Timmermans PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res. 1999;22:147-153.
10. van Kesteren CA, Saris JJ, Dekkers DH, Lamers JM, Saxena PR, Schalekamp MA, Danser AH. Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II. Cardiovasc Res. 1999; 43:148-156.
11. Hancock AA, Surber BW, Rotert G, Thomas S, Tasker AS, Sorensen BK, Vodenlich AD, Opgenorth TJ, Kerkman DJ and DeBernardis JF. [3H] A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. Eur J Pharmacol. 1994;267: 49-54.
12. van Zwieten PA. Angiotensin II receptor antagonists (AT1- blockers, ARBs, sartans): similarities and differences. Neth Heart J. 2006;14(11):381-387.
13. Vangala VB, Hindupur RM, Pati HN. A Review on Synthesis of Antihypertensive Sartan Drugs. Int J Pharm Res Rev. 2014;3:46-56.
14. Miura Si, Okabe A, Matsuo Y, Karnik SS, Saku K. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res. 2013;36:134-139.
15. Rakugi H, Kario K, Enya K, Igeta M, Ikeda Y. Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension. Blood Press. 2013;22(S1):22-28.4-139.
16. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13:81-88.
17. Hayashi N, Yoshikawa T, Ohnuma T, Higuchi H, Sako K, Uekusa H. Synthesis, Structure, and Properties of Benzoquinone Dimer and Trimers Bearing t-Bu Substituents. Org Lett. 2007;9:5417-5420.
18. Hayashi N, Yoshikawa T, Kurakawa M, Ohnuma T, Sugiyama Y, Higuchi H. Formation of Quinhydrone-Type Complexes Composed of Quinone Dimers and Trimers Bearing t-Butyl and n-Dodecyl Substituents. Mol Cryst Liq Cryst. 2006;456:133–137.
19. Hayashi N, Matsui K, Kanda A, Yoshikawa T, Nakagawa H, Yoshino J, Higuchi H. Exchange of Quinone and Hydroquinone Moieties in Mixed Solutions of Biquinone and Bihydroquinone. Chem Lett. 2011; 40: 947-949.
20. Naka T, Inada Y, Takeda Chem. Ind. U.S. Pat Appl. 1996;5,583,141.
21. Naka T, Inada Y, Takeda Chem. Ind. Eur Pat Appl. 1992; EP 0,520,423.
22. Kohara Y, Imamiya E, Kubo K, Wada T, Inada Y, Naka T. A new class of angiotensin II receptor antagonists with a novel acidic bioisostere. Bioorg Med Chem Lett. 1995;5:1903-1908.
23. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres. J Med Chem. 1996;39:5228-5235.
24. Kuroita T, Sakamoto H, Ojima M, Takeda Chem. Ind. U.S. Pat Appl. 2005;0,187,269.
25. Kuroita T, Sakamoto H, Ojima M, Takeda Chem. Ind. U.S. Pat Appl. 2007; 7,157,584.
26. Radl S, Cerny J, Stach J, Gablikova Z. Improved process for azilsartan medoxomil: a new angiotensin receptor blocker. Org Process Res Dev, 2013;17:77-86.
27. ICH Guideline: Impurities in New Drug Substances Q3A, (R2); International Conference on Harmonisation, 2006.
28. ICH Guideline: Impurities in New Drug Products Q3B, (R2); International Conference on Harmonisation, 2006.
29. Yoshikawa T, Matsushima D, Asao R, Hisa T, Nishikado H, Yamada A, Yokota M, Kanamori T. 特開2018-197206.
30. ICH Guideline：I.C.H. Q1A(R2), Stability testing of new drug substances and products, in:International Conference on Harmonization, IFPMA, Geneva, 2003.
31. ICH Guideline：I.C.H. Q1B, Stability testing: photostability testing of new drug substances andproducts, in: International Conference on Harmonization, IFPMA, Geneva,1998.
32. Kaushik K, Kaur J, Paul Kaur V, Saini B, Bansal Y, Bansal G. Forced Degradation, LC-UV, MSnand LC-MS-TOF Studies on Azilsartan: Identification of a Known and Three New Degradation Impurities. J Pharm Biomed Anal. 2016;120:202-211.
33. Dubai-Assibat N, Baceiredo A, Bertrand G. Synthesis and reactivity of the first spectroscopically observed 1H-diazirine. J Am Chem Soc. 1996; 118:5216–5220.
34. Shimbayashi T, Sasakura K, Eguchi A, Okamoto K.,Ohe K, Recent Progress on Cyclic Nitrenoid Precursors in Transition-Metal-Catalyzed Nitrene-Transfer Reactions. Chem Eur J. 2019;25:3156-3180.
35. Boyer JH, Ellis PS, Fragmentation-rearrangement of Δ3-oxadiazolin-5- and 3-ones. J Chem Soc Perkin Trans. 1979;1:483-487.
36. Boyer JH, Frints PJA. The azomethine nitrene. II. Photolysis of 3-phenyl-Δ2- oxadiazol-5-one. J Heterocyclic Chem. 1970;7(1):71-74.
37. Boyer JH, Frints PJA. The azomethine nitrene. I. Pyrolysis and photolysis of Δ21,2,4-oxadiazoline-5-ones. J Heterocycl. Chem. 1970;7(1):59-70.
38. Sauer J, Mayer K K. Thermolyse und photolyse von 3.4-Diphenyl-Δ 2-1.2.4- oxdiazolinon-(5) und 2.4-Diphenyl- Δ2-1.3.4-Oxdiazolinon．Tetrahedron Lett. 1968;3:325-330.
39. Bégué D, Dargelos A, Wentrup C, Rearrangements of Nitrile Imines: Ring Expansion of Benzonitrile Imines to Cycloheptatetraenes and Ring Closure to 3‑Phenyl‑3H‑diazirines. J Org Chem. 2019;84:8668-8673.
40. Marchais J, Bégué D, Dargelos A, Wentrup C, Rearrangements of Aromatic Nitrile Oxides and Nitrile Ylides: Potential Ring Expansion to Cycloheptatetraene Derivatives Mimicking Arylcarbenes, Chem Eur J. 2020; 26: 67:15700-15707.
41. ICH Guideline: I.C.H. Q1B, Stability Testing: Photostability Testing of New Drug Substances and Products .1997.
42. Sorouraddin MH, Amini K, Naseri A, Rashidi MR. Simultaneous spectrophotometric determination of phenanthridine, phenanthridinone and phenanthridine N-oxide using multivariate calibration methods. Cent Eur J Chem.2010:8(1);207-213.
43. Katritzky AR, Du W, Matsukawa Y, Ghiviriga I, Denisenko SN. Polycyclic fused phenanthridines: An alternative approach from benzotriazoles. J Heterocycl Chem. 1999;36:927-932.
44. Budén ME, Dorn V B, Gamba M, Pierini A B, Rossi R A. Electron-Transfer-Mediated Synthesis of Phenanthridines by Intramolecular Arylation of Anions from N-(ortho-Halobenzyl)arylamines: Regiochemical and Mechanistic Analysis. J Org Chem. 2010;75:2206-2218.
45. Wang Y-F, Lonca GH, Le Runigo M, Chiba S. Synthesis of Polyfluoroalkyl Aza- Polycyclic Aromatic Hydrocarbons Enabled by Addition of Perfluoroalkyl Radicals onto Vinyl Azides. Org Lett. 2014;16:4272-4275.
46. Pearson R, Zhang S, He G, Edwards N, Chen G. Synthesis of Phenanthridines via Palladium-Catalyzed PicolinamideDirected Sequential C-H Functionalization. Beilstein. J Org Chem. 2013;9:891-899.
47. Ghosh M, Ahmed A, Dhara S, Ray JK. Synthesis of phenanthridine and its analogues via aerobic ligand-free domino Suzuki coupling-Michael addition reaction catalyzed by in situ generated palladium-nanoparticles in water. Tetrahedron Lett. 2013;544837-4840.
48. Deb I, Yoshikai N. Phenanthridine Synthesis through Iron-Catalyzed Intramolecular N‑Arylation of O‑Acetyl Oxime. Org Lett. 2013;15:4254-4257.
49. McBurney RT, Walton JC. Interplay of Ortho- with SpiroCyclisation During Iminyl Radical Closures onto Arenes and Heteroarenes. Beilstein J Org Chem. 2013;9:1083-1092.
50. McBurney RT, Slawin AM, Smart LA, Yu Y, Walton JC. UV promoted phenanthridine syntheses from oxime carbonate derived iminyl radicals. Chem Commun. 2011;47:7974-7976.
51. Dabbagh HA, Ghaelee S. Functionalization of phenyl rings by imidoylnitrene 2. Cycloaddition or electrophilic aromatic substitution?. J Org Chem. 1996;61:3439-3445.
52. ICH Guideline: I.C.H. Ｍ７, ICH M7 – assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk .2015.
53. Test 471. Bacterial Reverse Mutation Test OECD Guideline for Testing of Chemicals Section 41997, July.
54. Foster R.S, Fowkes A, Cayley A, Thresher A, Werner A-L D, Barber C G, Kocks G, Tennant R.E, Williams R.V, Kane S, Stalford S.A. The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7 Genes and Environment. 2020;42:27.
55. Mishima M, Hashizume T, Haranosono Y, NagatoY, Takeshita K, Fukuchi J, Homma M. Meeting report, ICH M7 relevant workshop: use of (Q)SAR systems and expert judgment. Genes and Environment. 2018;40:19.
56. Foster RS, Fowkes A, Cayley A, Thresher A, Werner ALD, Barber CG, Kocks G, Tennant RE., Williams RV, Kane S, Stalford SA. The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7. Genes and Environment. 2020; 42: 27.
57. Homma M. An assessment of mutagenicity of chemical substances by (quantitative) structure–activity relationship. Genes and Environment. 2020;42:23.
58. Kazius J, McGuire R, Bursi R, Derivation and validation of toxicophores for mutagenicity prediction. J Med Chem. 2005, 48, 312– 320.
59. Burczynski ME, Lin HK, Penning TM. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalysed by human dihydrodiol dehydrogenase. Cancer Res. 1999;59:607-614.
60. Borosky G.L, Carcinogenic carbocyclic and heterocyclic aromatic amines: ADFT study concerning their mutagenic potency. J Mol Graph Model. 2008: 27;459-465.
61. Benigni R, Bossa C. Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. Chem Rev. 2011;111:2507- 2536.
62. Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K. Salmonella mutagenicity tests. v. results from the testing of 311 chemicals. Environ Mol Mutagen. 1992;19: 2-141.
63. Matsumoto T, Yoshida D, Mizusaki S, Tomita H, Koshimizu K. Structural requirements for mutagenic activities of N-heterocyclic bases in the Salmonella test system. Agric Biol Chem. 1978;42:861-864.
64. Matsumoto T, Yoshida D, Mizusaki S, Tomita H, Koshimizu K. Activities of N Heterocyclic Bases in the Salmonella Test System. Agric Bio Chem. 1978;42(4):861-864.
65. Abe S, Sasaki M. Chromosome aberrations and sister chromatic exchanges in Chinese hamster cells exposed to various chemicals. J Natl Cancer Inst. 1977;58:1635-1641.
66. Ishidate M, Jr, Odashima S. Chromosome tests with 134 compounds on Chinese hamster cells in vitro – A screening for chemical carcinogens. Mutat Res. 1977;48:337-354.
67. Bomhard EM. High-dose clastogenic activity of aniline in the rat bone marrow and its relationship to the carcinogenicity in the spleen of rats. Arch Toxicol. 2003 77: 291-297.
68. Ahlberg E, Amberg A, Beilke LD, Bower D, Cross KP, Custer L, Dobo K, Ford KA, VanGompel J, Harvey J, Honma M, Jolly R, Joossens E, Kemper R, Kenyon M, Kruhlak N, Kuhnke L, Leavitt P, Neilan C, Naven R, Quigley DP, Shuey D, Spirkl HP, Stavitskaya L, Teasdale A, White A, Wichard J, Zwickl C, Myatt GJ. Extending (Q)SARs to incorporate proprietary knowledge for regulatory
purposes: a case study using aromatic amine mutagenicity. Regul Toxicol Pharmacol. 2016;77:1-12.
69. Kazius J, McGuire R, Bursi R. Derivation and Validation of Toxicophores for Mutagenicity Prediction. J Med Chem. 2005;48(1): 312-320.
70. Benigni R. Structure_activity relationship studies of chemical mutagens and carcinogens: mechanistic investigations and prediction approaches. Chem Rev. 2005;105:1767-1800.
71. Benigni R, Bossa C. Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. Chem Rev. 2011;111(4):2507-2536.
72. Benigni R, Bossa C. Structure alerts for carcinogenicity, and the Salmonella assay system: A novel insight through the chemical relational databases technology. Mutat Res. 2008;659(3):248-261.
73. Glende C, Klein M, Schmitt H, Erdinger L, Boche G, Transformation of mutagenic aromatic amines into non-mutagenic species by alkyl substituents. Part II: alkylation far away from the amino function. Mutat Res. 2002;515: 15-38.
74. Hara, Y.; Nagaoka, S.; Genda, K. In Drug Discovery in Japan, Investigating the Sources of Innovation; Sadao N.; Springer, 2019; pp 51-63.
75. Quirk J, Thornton M, Kirkpatrick P. Rosuvastatin calcium. Nat Rev Drug Discov. 2003;2,: 769–770.
76. Carter N. Rosuvastatin. Am J Cardiovasc Drugs. 2010;10(6):383-400.
77. Litvic M, Smic K, Vinkovic V, Filipan-Litvic M. A study of photodegradation of drug rosuvastatin calcium in solid state and solution under UV and visible light irradiation: The influence of certain dyes as efficient stabilizers. J Photoch Photobio A. 2013;252:84-92.
78. D-Cordonnier MH, Hildebrand M-P, Baldeyrou B, Lansiaux A, Keuser C, Benzschawe K, , Lemster T, Pindur U. Design, synthesis and biological evaluation of new oligopyrrole carboxamides linked with tricyclic DNA-intercalators as potential DNA ligands or topoisomerase inhibitors. J Med Chem. 2007;42:752- 771.
79. Loza-Mejia MA, Castillo R, Lira-Rocha A. Molecular modeling of tricyclic compounds with anilino substituents and their intercalation complexes with DNA sequences. J Mol Graph Model. 2009. 27: 900-907.
80. Watanabe M. Koike H. Ishiba T, Okada T, Seo S, Hirai K. Synthesis and biological activity of methane sulfonyl pyrrole-substituted 3.5-dihydroxy-6 heptanoates: a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem. 1997; 5: 437-444.
81. Dandala R. Mallela S. P. S, Garimella N. K. A. S. S, Nandi S. Buridipad S. K, Nangi G. B. S, Meenakshisunderam S. PCT Pat. Appl. WO 2,008,053,334, 2008; Chem. Abstr. 2008, 148, 537968.
82. Huang Q. PCT Pat. Appl. WO 2,006,076,845, 2006; Chem. Abstr. 2006, 145, 188897.
83. A. Hobson L, Akiti O, S. Deshmukh S, Harper S, Katipally K, J. Lai C, C. Livingston R, Lo E, M. Miller M, Ramakrishnan S, Shen L, Spink J, Tummala S, Wei C, Yamamoto K, Young J, L Parsons R. Development of a scaleable process for the synthesis of a next-generation Statin. Org Process Res Dev. 2010; 14: 441-458.
84. Brodfuehrer, P. R, Sattelberg T. R. Sr, Kant J, Qian X, PCT Pat. Appl. WO 2,002,098,854, 2002; Chem Abstr. 2002, 138, 24717.
85. Knoevenagel E. Emil Knoevenagel. Angew Chem. 1922; 35: 29-30.
86. Speri E, Kim C, De Benedetti S, Qian Y, Lastochkin E, Fishovitz J, F Fisher J, Mobashery S. Cinnamonitrile Adjuvants Restore Susceptibility to β-Lactams against Methicillin-Resistant Staphylococcus aureus. Med Chem Lett. 2019; 10:1148-1153.
87. Brfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Prez S, Heckroth H, Nitsche A, Ergden J, Gielen-Haertwig H, Schlemmer K, Mittendorf J, Paulsen H, Platzek J, Kolkhof P. Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases. Chem Med Chem. 2012; 7: 1385-1403.
88. de Silva S. O, Ahmad I, Snieckus V. A convergent route to phthalide isoquinoline alkaloids via directed metalation of tertiary benzamides. Can J Chem. 1979; 57; 1598-1605.
89. Kini A, Mays M, Cowan D. Tetramethyltetracyanoquinodimethane. J Chem Soc Chem Commun. 1985: 286-287.
90. Tietze, L.F.; Beifuss, U. in Comprehensive Organic Synthesis. 2nd ed.; Trost, B.M. Ed.; Pergamon: Oxford, 1991;Vol. 2, pp. 341-394
91. Zabicky J. 137. The kinetics and mechanism of carbonyl–methylene condensation reactions. Part XI. Stereochemistry of the products. J Chem Soc. 1961: 683-687.
92. Baker W, Howes C. 22. Stereochemistry of arylidenecyanoacetic acids and arylarylideneacetonitriles. J Chem Soc. 1953: 119-124.
93. Cho H, Iwashita T, Hamaguchi M, Oyama Y. Stereochemistry of Knoevenagel Condensation Products from Cyanoacetates and Aromatic Aldehydes. Chem Pharm Bull. 1991; 39: 3341-3342.
94. Hayahsi T. Studies on Geometric Isomerism by Nuclear Magnetic Resonance. III. Stereochemistry of α-Cyanocinnamic Esters. J Org Chem. 1966; 31: 3253- 3258.
95. Zhao Z, He B, Nie H, Chen B, Lu P, Qin , B. Z. Tang B.Z. Stereoselective synthesis of folded luminogens with arene–arene stacking interactions and aggregation-enhanced emission. Chem Commun. 2014; 50: 1131-1133.
96. Šterk D, Zaugg W, Beutler U, M. Loeser E, Prasad K, Cˇ asar, Z. Efficient and highly stereoselective assembly of rosuvastatin. Tetrahedron Lett. 2016; 57: 1338-1341.
97. Huang Q. PCT Pat. Appl. WO 2,006,076,845, 2006; Chem Abstr. 2006, 145, 188897.
98. C. Cope A. Condensation Reactions. I. The Condensation of Ketones with Cyanoacetic Esters and the Mechanism of the Knoevenagel Reaction. J Am Chem Soc. 1937; 59: 2327-2330.
99. C. Cope A, M. Hofmann C, Wyckoff C, Hardenbergh E. Condensation Reactions. II. Alkylidene Cyanoacetic and Malonic Esters. J Am Chem Soc. 1941; 63: 3452-3456.
100. Happer D.A.R, Steenson B.E. Preparation of α,β-Unsaturated Sulfones by the Knoevenagel Method. Synthesis. 1980; 10: 806-807.
101. Dressler H, Graham J.E. beta.-Cyano- and beta.-carbethoxy sulfides, sulfoxide, and sulfones and their Knoevenagel condensation. J Org Chem. 1967; 32: 985- 990.
102. Tanikaga R, Tamura T, Nozaki Y, Kaji A. Selective synthesis of α-sulphenyl-,α-sulphinyl-, and α-sulphonyl-α,β-unsaturated carbonyl compounds by the knoevenagel reaction. J Chem Soc Chem Commun. 1984: 87-88.
103. Tan C. Y. K, Weaver D. F. A one-pot synthesis of 3-amino-3-arylpropionic acids. Tetrahedron, 2002; 58: 7449-7461.
104. Migues A.N, Sun Q, Vaitheeswaran S, Sherman W, Auerbach S.M. On the Rational Design of Zeolite Clusters for Converging Reaction Barriers: Quantum Study of Aldol Kinetics Confined in HZSM-5. J Phys Chem C. 2018; 122: 23230- 23241.
105. Noyce D. S, Reed W. L. Carbonyl Reactions. VI. Evidence for Alternate Mechanisms for the Dehydration of β-Hydroxy Ketones. J Am Chem Soc. 1958; 80: 5539-5542.
106. Sturgeon M. R, Kim S, Lawrence K, Paton R. S, Chmely S. C, Nimlos M, Foust T. D, Beckham G. T. A Mechanistic Investigation of Acid-Catalyzed Cleavage of Aryl-Ether Linkages: Implications for Lignin Depolymerization in Acidic Environments. ACS Sustainable Chem Eng. 2014; 2: 472-485.
107. Bondi A. van der Waals Volumes and Radii. J Phys Chem. 1964; 68: 441-451.
108. Huang TH, Yang H, Yang G, Zhu SL, Zhang CL. Synthesis, structural characterization and photoluminescent properties of copper (I) coordination polymers with extended C–H⋯ π and CN⋯ π interactions. Inorg Chim Acta. 2017; 455: 1-8.
109. Tian Z.F, Ren X.M, Li Y.Z, Song Y, Meng Q.J. A New Quasi-1D Spin System with Spin Transition Exhibiting Novel CN···π Interactions. Inorg Chem. 2007; 46: 8102-8104.
110. Tian Z.F, Duan HB, Zhou H, Ren XM, Zhang H, Meng QJ. An intriguing NO2⋯π and CN⋯π interactions in [1-(4'-nitrobenzyl)pyrazinium][Ni(mnt)2]: Crystal structure, magnetic property and DFT calculation. Inorg Chem Commun.2009; 12: 148-150.
論文の公開元へ
